BFA
MBRX icon

BlackRock Fund Advisors’s Moleculin Biotech MBRX Stock Holding History

BlackRock Fund Advisors’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$41K Buy
+8
New +$53.6K ﹤0.01% 3796

Other funds holding MBRX

Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AWMS
Advocacy Wealth Management Services Atlanta, Georgia $2.75B AUM 19.24% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
NFG
Next Financial Group Houston, Texas $1.52B AUM 20.14% 1-Year Est. Return
WA
WFG Advisors Dallas, Texas $442M AUM 12.46% 1-Year Est. Return

BlackRock Fund Advisors's MBRX Position: Q4 2016 in Review

BlackRock Fund Advisors opened a new position in Moleculin Biotech (MBRX) in Q4 2016: 8 shares worth $41K. The stake represents ﹤0.01% of the portfolio and ranks #3796 among its holdings.

6 funds tracked by Wall St. Rank hold MBRX as of Q4 2016.

  • BlackRock Fund Advisors held 8 shares of Moleculin Biotech worth $41K as of Q4 2016.
  • Moleculin Biotech was a new BlackRock Fund Advisors position in Q4 2016.
  • Moleculin Biotech made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #3796 holding.
  • 6 funds tracked by Wall St. Rank held Moleculin Biotech as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.